Stock listing
AQST Stock Price, News, Filings & Events — Aquestive Therapeutics, Inc.
Selected listing: AQST · NASDAQ · USD · US
This page tracks Aquestive Therapeutics, Inc.'s AQST:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AQST:NASDAQ. AQST:NASDAQ is the stock-level entry point for investors researching Aquestive Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Aquestive Therapeutics, Inc. is a public company traded under the ticker AQST in the American market. The company has a market capitalization of approximately $461.7 million. It focuses on developing innovative therapeutics to address unmet medical needs.
- Ticker
- AQST:NASDAQ
- Asset type
- Stock
- Market cap
- $584.9M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Aquestive Therapeutics, Inc. AQST:NASDAQ stock context
This page tracks Aquestive Therapeutics, Inc.'s AQST:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AQST:NASDAQ. AQST:NASDAQ is the stock-level entry point for investors researching Aquestive Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Aquestive Therapeutics, Inc. is a public company traded under the ticker AQST in the American market. The company has a market capitalization of approximately $461.7 million. It focuses on developing innovative therapeutics to address unmet medical needs.
Latest news from Aquestive Therapeutics, Inc.
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Ca...
July 29, 2026
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
May 12, 2026
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call o...
May 6, 2026
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
March 30, 2026
Aquestive Therapeutics, Inc. earnings calls
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call
August 12, 2026 · Replay with transcript and chapters
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call
May 14, 2026 · Replay with transcript and chapters
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call
March 5, 2026 · Replay with transcript and chapters
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call
November 6, 2025 · Replay with transcript and chapters
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call
August 12, 2025 · Replay with transcript and chapters
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call
May 13, 2025 · Replay with transcript and chapters
Research Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for AQST:NASDAQ.
Aquestive Therapeutics, Inc. company profile
View the public company page for Aquestive Therapeutics, Inc. on 6ix.
Aquestive Therapeutics, Inc. news
Read company news and market updates connected to Aquestive Therapeutics, Inc..
Aquestive Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Aquestive Therapeutics, Inc..